Performance Evaluation Of Betta Pharmaceutical Merging Kananji Medicine

The development of pharmaceutical manufacturing industry is closely related to the national economy and people’s livelihood.With the outbreak of COVID-19,the public’s health awareness has been further improved,and the demand for medical and health resources has been constantly expanding.Influenced by this,the pharmaceutical manufacturing industry has developed rapidly in recent years.However,as the state for the pharmaceutical industry entry requirements are increasingly strict,with procurement,medical fees and other related policies introduced gradually,pharmaceutical manufacturing industry has entered a stage of development,a strict and high standard development speed slow,this will lead to industry more competitive,companies tend to choose positive mergers-and-acquisitions expansion strategy to promote their own development.How to maximize the market competitiveness through mergers and acquisitions has become an urgent problem for most enterprises.Based on this,this thesis chooses the typical M&A event of Betta Pharmaceutical and Kananji Pharmaceutical as the research object.Firstly,based on the current situation of the pharmaceutical manufacturing industry in China,the M&A parties and the M&A process are introduced to induce M&A motivations.Secondly,the event study method is used to evaluate the short-term market performance of mergers and acquisitions,and the balanced scorecard is used to evaluate the long-term performance of Betta Pharmaceutical after the completion of mergers and acquisitions,and the reasons for the change of performance evaluation indicators are analyzed.Then,according to the index evaluation system constructed by the balanced scorecard,the entropy method is used for objective weighting,and the overall performance score of Betta Pharmaceutical after merger and acquisition is calculated.The results show that from the perspective of short-term performance,the M&A has achieved a relatively good market response;From the point of long-term performance,betta pharmaceutical performance index of the multiple dimensions of a steady rise,although the performance of the financial dimension at the beginning of the m&a fell,but with the deepening of the internal integration and gradually improve,it is worth noting that the financial dimension of a significant decline in 2021,so the m&a performance evaluation for a long time still remains to be seen.In addition,the calculation results of entropy method also support the performance evaluation conclusion of BSC.Finally,based on the research of this thesis,relevant optimization suggestions are put forward for Betta Pharmaceutical to improve the performance of mergers and acquisitions,and the relevant enlightenment of mergers and acquisitions in the pharmaceutical manufacturing industry is summarized from the process of mergers and acquisitions,in order to provide reference for enterprises in the same industry to carry out mergers and acquisitions.